<VariationArchive VariationID="619247" VariationName="GRCh37/hg19 16p13.3(chr16:3794894-3795355)" VariationType="copy number loss" Accession="VCV000619247" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2019-03-14" MostRecentSubmission="2019-03-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="610645" VariationID="619247">
      <GeneList>
        <Gene Symbol="CREBBP" FullName="CREB binding protein" GeneID="1387" HGNC_ID="HGNC:2348" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3725054" stop="3880713" display_start="3725054" display_stop="3880713" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3775054" stop="3930120" display_start="3775054" display_stop="3930120" Strand="-" />
          </Location>
          <OMIM>600140</OMIM>
          <Haploinsufficiency last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>GRCh37/hg19 16p13.3(chr16:3794894-3795355)</Name>
      <VariantType>copy number loss</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="3794894" innerStop="3795355" display_start="3794894" display_stop="3795355" variantLength="462" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_3794894)_(3795355_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_3794894)_(3795355_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="GRCh37/hg19 16p13.3(chr16:3794894-3795355) AND Rubinstein-Taybi syndrome due to CREBBP mutations" Accession="RCV000754906" Version="4">
        <ClassifiedConditionList TraitSetID="1898">
          <ClassifiedCondition DB="MedGen" ID="C4551859">Rubinstein-Taybi syndrome due to CREBBP mutations</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-03-14" MostRecentSubmission="2019-03-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1898" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4360" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to CREBBP mutations</ElementValue>
                <XRef ID="MONDO:0008393" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Broad thumbs and great toes, characteristic facies, and mental retardation</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE</ElementValue>
                <XRef Type="Allelic variant" ID="600140.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600140.0005" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CREBBP</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RTS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RSTS1</ElementValue>
                <XRef Type="MIM" ID="180849" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">CREBBP-Related Rubinstein-Taybi Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17534" />
                <XRef ID="17534" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353277" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C4551859" DB="MedGen" />
              <XRef ID="MONDO:0008393" DB="MONDO" />
              <XRef Type="MIM" ID="180849" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1518277" SubmissionDate="2018-12-11" DateLastUpdated="2019-03-14" DateCreated="2019-03-14">
        <ClinVarSubmissionID localKey=":Chr.16_3794894_3795355_copy number loss|OMIM:180849" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000778561" DateUpdated="2019-03-14" DateCreated="2019-03-14" Type="SCV" Version="1" SubmitterName="Center for Molecular Medicine, Childrenâ€™s Hospital of Fudan University" OrgID="506025" OrganizationCategory="clinic" OrgAbbreviation="CMM-CHFU" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-07-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>de novo</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Read depth</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CREBBP" />
          </GeneList>
          <VariantType>copy number loss</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="16" innerStart="3794894" innerStop="3795355" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Rubinstein-Taybi syndrome-1</ElementValue>
            </Name>
            <XRef DB="OMIM" ID="180849" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3777990</SubmissionName>
          <SubmissionName>SUB4902981</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1518277" TraitType="Disease" MappingType="Name" MappingValue="Rubinstein-Taybi syndrome-1" MappingRef="Preferred">
        <MedGen CUI="C4551859" Name="Rubinstein-Taybi syndrome due to CREBBP mutations" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

